Analytic tool designed to help guide precision oncology
The tool, called TransPRECISE, uses data from 7,714 patient samples across 31 cancer types, collected as part of the Cancer Proteome Atlas. This is combined with 640 cancer cell lines from the MD Anderson Cell Lines Project and drug sensitivity data representing 481 drugs from the Genomics of Drug Sensitivity in Cancer model system.
The global Liquid Biopsy Market is projected to expand from USD 3.8 billion in 2023 to USD 9.4 billion by 2032, growing at a robust CAGR of 10.7% during the forecast period (2024–2032). This rapi...
shared news
shared news
